Century Therapeutics SVP covers taxes via share sale

Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of 7,043 shares of common stock at $2.549 per share on March 12, 2026.

Rhea-AI Filing Summary

Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of 7,043 shares of common stock at $2.549 per share on March 12, 2026. The filing describes this as an open-market transaction.

According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units and the sale was not at his discretion. After the transaction, Carr still directly holds 507,261 shares of Century Therapeutics common stock.

Insider Trade Summary

Net Seller: 7,043 shares

Net Sell 1 txn

Insider Carr Douglas

Role SVP Finance & Operations

Sold 7,043 shs ($18K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,043	$2.549	$18K

Holdings After Transaction: Common Stock — 507,261 shares (Direct)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Century Therapeutics (IPSC) report for Douglas Carr?

Century Therapeutics reported that SVP Finance & Operations Douglas Carr sold 7,043 shares of common stock at $2.549 per share. The shares were sold automatically to cover tax withholding obligations related to restricted stock unit vesting, rather than a discretionary open-market sale.

Why did Douglas Carr sell shares of Century Therapeutics (IPSC)?

Douglas Carr sold 7,043 Century Therapeutics shares to cover tax withholding obligations from vesting restricted stock units. The footnote states these sales were automatic and not at his discretion, indicating a tax-related, administrative transaction rather than a voluntary portfolio decision.

How many Century Therapeutics (IPSC) shares does Douglas Carr still own after the sale?

After the reported sale, Douglas Carr directly holds 507,261 shares of Century Therapeutics common stock. This shows that the 7,043 shares sold to cover tax withholding obligations represent a relatively small portion of his overall reported share position in the company.

What was the sale price in the Century Therapeutics (IPSC) Form 4 filing?

The Form 4 filing shows that the 7,043 Century Therapeutics common shares were sold at a price of $2.549 per share. This price applies to the tax-related, automatic transaction executed to satisfy withholding obligations on vesting restricted stock units.

Is the Century Therapeutics (IPSC) insider sale by Douglas Carr a discretionary trade?

The filing explains that Douglas Carr’s sale was not discretionary. The 7,043 shares of Century Therapeutics common stock were sold automatically to cover tax withholding obligations linked to the vesting of restricted stock units, rather than being an elective open-market sale decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Finance & Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S(1)		7,043	D	$2.549	507,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.